OrbiMed, Novo Holdings and Jeito Capital led a $181.4m Series D in Alentis Therapeutics.

Private equity firms OrbiMed, Novo Holdings and Jeito Capital, led a $181.4m Series D in Alentis Therapeutics, clinical-stage biotechnology company, with participation from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, RA Capital Management, Morningside Venture Investments, BB Pureos, Bpifrance and InnoBio. “This financing is a testament to the transformational potential of CLDN1 antibody-drug conjugates (ADCs) for the treatment of solid tumors. Let me take this opportunity to extend a warm welcome to our new investors.” Dr. Iacone added, “We're excited to execute our development strategy and deliver clinical data for our programs over the next 12-18 months,” Roberto Iacone, Alentis Chief Executive Officer.